Vision Loss News and Research

RSS

Exonate plans 'CLEAR-DE' Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb clinical trial for its lead candidate EXN407.

29 Jul 2025

UC Davis researchers pioneer safer gene therapy for vision loss

The UC Davis Department of Ophthalmology has received a five-year, $3.6 million grant from the National Eye Institute to explore a new way to treat vision loss using gene therapy.

22 Jul 2025

Emerging therapies reshape the future of AMD treatment

Age-related macular degeneration (AMD) remains a leading cause of vision loss globally, with significant advancements in treatment options for both dry and wet AMD.

18 Jul 2025

New data confirms efficacy of mitochondrial donation in preventing disease

The UK's pioneering licensed IVF technique to reduce the risk of mitochondrial diseases carried out in Newcastle has seen eight babies born, published research shows.

17 Jul 2025

New research offers hope to preserve vision in autosomal dominant optic atrophy

Autosomal dominant optic atrophy (ADOA), the most common genetic optic neuropathy, is an insidious disease. It often presents slowly during childhood by way of blurry vision, trouble reading or focusing, and sometimes only as a failed vision test.

16 Jul 2025

AI and eye scans reveal better way to predict risk from short-sightedness

A combination of routine eye scans and AI has created a powerful new way for measuring short-sightedness to better predict people's long-term risk of serious retinal damage, a new study suggests.

15 Jul 2025

Novel AI-powered retina tracker detects eye disease in under one second

A novel AI-powered retina tracker can analyze retinal images with near-perfect accuracy in under one second, according to a study being presented Monday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

15 Jul 2025

Circadian misalignment in the blind may impact daily brain functions

This study investigates how blindness affects sleep, dreams, and spatial awareness, revealing links between circadian rhythms and cognitive performance.

7 Jul 2025

Developmental visual experience may shape brain architecture

Incoming information from the retina is channeled into two pathways in the brain's visual system: one that's responsible for processing color and fine spatial detail, and another that's involved in spatial localization and detecting high temporal frequencies.

3 Jul 2025

Common autoimmune drug shown to help patients with giant cell arteritis

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of Medicine at the University of Pennsylvania published in the New England Journal of Medicine.

25 Jun 2025

Targeting ADAM10 may offer hope for retinal disease treatment

New research has found that the endothelial cell-specific A disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) regulates abnormal blood vessel growth in the damaged retina, which can cause vision loss or impairment.

25 Jun 2025

Study identifies potential way to slow or block progression of age-related macular degeneration

A new study from Washington University School of Medicine in St. Louis identifies a possible way to slow or block progression of age-related macular degeneration, a leading cause of blindness in people over age 50.

24 Jun 2025

Instant coffee may damage your eyes, genetic study finds

Researchers used genomic and Mendelian randomization analyses in over 500,000 individuals to reveal a statistically significant causal link between instant coffee intake and increased risk of dry age-related macular degeneration (AMD). No such risk was found for ground or decaffeinated coffee.

17 Jun 2025

FDA approves ENCELTO implant to preserve sight in people with macular telangiectasia type 2

For people diagnosed with macular telangiectasia type 2 (MacTel)-a rare and slowly progressing retinal disease-there have been no FDA-approved (or other) treatments to slow or stop vision loss.

4 Jun 2025

Oral 8-aminoguanine protects aging eyes and preserves vision in preclinical study

Oral 8-aminoguanine (8-AG) treatment preserved retinal structure and rod function in aged Fischer 344 rats, significantly reducing oxidative stress and inflammation. These findings highlight the promise of 8-AG as a non-invasive intervention to slow age-related retinal degeneration.

27 May 2025